Pamufetinib
- Generic Name
- Pamufetinib
AB122 Platform Study
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2021-08-11
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Target Recruit Count
- 715
- Registration Number
- NCT04999761
- Locations
- 🇯🇵
A site selected by Taiho Pharmaceutical Co., Ltd., Wakayama, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath